

◆ COVID-19-iPSC-INCKBN-002#1 (iPS cells derived from convalescent donor)

<b>Clone ID</b>	COVID-19-iPSC-INCKBN-002#1	<b>Product</b>	Human iPS cells
<b>Source</b>	Peripheral Blood, Human	<b>Race</b>	Japanese
<b>Passage No.</b>	7	<b>Gender</b>	Female
<b>Label Name</b>	20M84	<b>Manufacture Dates</b>	Dec. 7 <sup>th</sup> , 2020
<b>Culture medium</b>	StemFit AK03N	<b>Substrate</b>	iMatrix-511MG
<b>Culture Method</b>	Feeder-free <sup>(※2)</sup>		
<b>Reprogramming Method</b>	Sendai Virus vector (CytoTune-iPS2.0)		
<b>Use and Provision of this cell stock</b>	Please check our web site ; <a href="https://www.cira-foundation.or.jp/e/project/index.html">https://www.cira-foundation.or.jp/e/project/index.html</a>		

(※1) Reference; Nakagawa, *et. al.*, Nat Biotechnol. 2008 26(1):101-106

**Test Result**

Test	Method	Result
<b>SARS-CoV-2</b>	RT-PCR	Negative
<b>Sterility</b>	BacT/ALERT	Negative
<b>Mycoplasma</b>	PCR	Negative
<b>Endotoxin</b>	LAL	≤ 5 EU/mL
<b>Virus</b> ( HBV, HCV, HIV1/2, HTLV, Parvo B19, EBV, CMV)	PCR	Negative
<b>Morphology</b>	Microscope	Consistent with human ES cells
<b>STR genotyping</b>	PCR	Consistent with the donor cells
<b>Karyotype</b>	G-banding	46,XX[20]
<b>Vector remnants</b>	qPCR	Below the limit of quantification
<b>CNV<sup>(※2)</sup></b>	WGS, SNP	De novo CNV (DICER1) was found on Chr14.
<b>SNV/Indel<sup>(※3)</sup></b>	WGS	No de-novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.88) and Shibata list <sup>(※4)</sup> .
<b>Undifferentiated markers</b>	Flow cytometry	TRA-1-60: 95.3 % SSEA4: 99.9 % TRA-2-49: 98.2 % Oct3/4: 99.7 %
<b>Thawed postnatal cells</b>	Counting the number of the cells <sup>(※5)</sup>	3.55 × 10 <sup>5</sup> cells (Survival rate ; 71.0%)
<b>Number of proliferating cells after thawing</b>	Counting the number of the cells after culturing for 6 days <sup>(※5)</sup> .	23.3 × 10 <sup>5</sup> cells (Number of seeded cells : 1.5 × 10 <sup>5</sup> cells)


(※2) CNV; Copy Number Variation

(※3) SNV/Indel; Single nucleotide variants /Insertion Deletion

(※4) The PMDA Science Board “Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials” (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)

(※5) ThermoFisher Countess II®

## ■ Image



Please contact us if you have any questions.

[\(\[ips-request@cira-foundation.or.jp\]\(mailto:ips-request@cira-foundation.or.jp\)\)](mailto:ips-request@cira-foundation.or.jp)



Reprint or reproduction of this page without permission is prohibited.